TABLE 1.
Comparative demographics of patients receiving cefepime for VAP between the experimental and validation groups
| Characteristica | Experimental group (n = 26)
|
Validation group (n = 6)
|
||||
|---|---|---|---|---|---|---|
| Mean ± SD | Median (range) | No. (%) of patients | Mean ± SD | Median (range) | No. (%) of patients | |
| Continuous variables | ||||||
| Age | 57.0 ± 21.3 | 60.5 (19-91) | 62.0 ± 8.3 | 63.5 (49-72) | ||
| Wt (kg) | 84.0 ± 23.2 | 78.6 (50.4-158.4) | 86.9 ± 15.7 | 85.4 (70.5-106.8) | ||
| APACHE II scoreb | 19.5 ± 4.6 | 19 (11-29) | 18.3 ± 5.0 | 16.5 (15-28) | ||
| SCr (mg/dl) | 0.9 ± 0.4 | 0.8 (0.4-2.3) | 1.0 ± 0.5 | 0.9 (0.4-1.8) | ||
| CLCR (ml/min)c | 100.5 ± 40.7 | 97.5 (26.1-186.7) | 93.7 ± 56.2 | 80.7 (40.6-193.4) | ||
| Dichotomous variables | ||||||
| Male gender | 17 (65) | 4 (67) | ||||
| ICU type | ||||||
| SICU | 13 (50) | 3 (50) | ||||
| NTICU | 13 (50) | 3 (50) | ||||
| Concomitant treatment with: | ||||||
| Tobramycin | 19 (73) | 5 (83) | ||||
| Vancomycin | 22 (85) | 5 (83) | ||||
| Fluoroquinolone | 4 (15) | 0 (0) | ||||
| Tobramycin + vancomycin | 18 (69) | 5 (83) | ||||
a
SICU, surgical intensive care unit; NTICU, neurotrauma intensive care unit; SCr, serum creatinine; CLCR, creatinine clearance.
b
APACHE II score was measured at the time of the first blood sample from the patient.
c
CLCR was calculated using the Cockcroft-Gault equation, independent of weight.